Overview of the safety of newer antiepileptic drugs

Epilepsia

Volumn 38, Issue SUPPL. 1, 1997, Pages

  Shorvon, S ^a   Stefan, H ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Anti convulsants; Drug toxicity; Felbamate; Gabapentin; Lamotrigine; Tiagabine; Topiramate; Vigabatrin

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

AMBLYOPIA; ATAXIA; CONFERENCE PAPER; DIPLOPIA; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; EPILEPSY; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL; RASH; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0030946333     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb04519.x     Document Type: Conference Paper

References (79)

1. Schmidt D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982.
2. Pellock JM, Pippenger CE, Adverse effects of antiepileptic drugs. In: Dodson WE, Pellock JM, eds. Pediatric epilepsy: diagnosis and therapy. New York: Demos, 1993:253-64.
3. Pellock JM. Standard approach to antiepileptic drug treatment in the United States. Epilepsia 1994;35(suppl 4):11-8.
4. Chadwick D. Standard approach to antiepileptic drug treatment in the United Kingdom. Epilepsia 1994;35(suppl 4):S3-10.
5. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Safety 1993;9:156-84.
6. Messenheimer JA. Lamotrigine, Epilepsia 1995;36(suppl 2):S87-94.
7. Lamotrigine. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics, 1996:1112-7.
8. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:693-6.
9. Leestma JE, Annegers JF, Brodie MJ, et al. Incidence of sudden unexplained death in the Lamictal® (lamotrigine) clinical development program. Epilepsia 1994;35(suppl 8):S12.
10. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995;36(suppl 5):S1-7.
11. Jawad S, Yuen AWC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamoirigine: single dose pharmacokinetics and initial one week exposure in refractory seizures. Epilepsy Res 1987;1:196-201.
12. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
13. Leppik IE. Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994;35(suppl 4):29-40.
14. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol 1995;33:595-7.
15. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BMJ 1995;310:10:504.
16. Sander JWS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13:89-92.
17. Betts T. Clinical uses of lamotrigine. Seizure 1992;1:3-6.
18. Ben-Menachem E. Vigabatrin. Epilepsia 1995;36(suppl 2):S95-104.
19. Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38.
20. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27(suppl l):43-5.
21. Jackson GD, Williams SF, van Bruggen N, et al. Vigabatrin-induced cerebellar and cortical lesions are demonstrated by quantitative magnetic resonance imaging, Epilepsia 1991;32 (suppl 1):S13.
22. Weiss KI, Schroeder CE, Kashin S, et al. Vigabatrin induced intramyelinic Oedema II. Effects on MRI in dogs. Neurology 1991;41(suppl 1):351.
23. Sussman NM, Weiss KI, Schroeder CE. Vigabatrin: effect on in vitro and ex vivo magnetic resonance imaging of dog brains. Epilepsia 1991;32(suppl 1):S13.
24. Cocito L, Maffini M, Loeb C. MRI findings in epileptic patients on vigabatrin for more than five years. Seizure 1992;1:163-5.
25. Hammond EJ, Wilder BJ, Hurd RW. Eight-year experience with vigabatrin: clinical neurophysiologic, neuropathologic studies. Epilepsia 1991;32(suppl 1):11.
26. Mumford JP. Vigabatrin (Sabril): the strategy for preclinical and clinical evaluation. Boll Lega It Epil 1994;86/87:19-23.
27. Cannon DJ, Butler WH, Mumford JP, et al. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neural 1991;6:17-24.
28. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
29. Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry 1989;52:467-71.
30. Brodie MJ, McKee PJW. Vigabatrin and psychosis. Lancet 1990;335:1279.
31. Ring HA, Reynolds EH. Vigabatrin and behavior disturbances. Lancet 1990;335:970.
32. Sander JWAS, Hart YM. Vigabatrin and behavior disturbances. Lancet 1990;335:57.
33. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54:435-9.
34. Betts T. Management of psychotic reactions related to the use of vigabatrin. Epilepsia 1993;34(suppl 2):S118.
35. Wong ICK. Retrospective study of vigabatrin and psychiatric behavioral disturbances. Epilepsy Res 1995;21:227-30.
36. Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behavior disorders: a retrospective survey. Epilepsy Res 1996;25:21-7.
37. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27:27S-33S.
38. Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the management of epilepsy in children. Br J Clin Pharmacol 1989;27:109S-12S.
39. Matilainen R, Pitkainen A, Ruutiainen T, et al. Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. Neurology 1988;38:743-7.
40. Reḿy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989;27:125S-9S.
41. McLean MJ. Gabapentin. Epilepsia 1995;36(suppl 2):S73-86.
42. Gabapentin. Physicians' Desk Reference. Montvale, NJ; Medical Economics, 1996:1922-4.
43. Bauer G, Bechinger D, Castell M, et al. Gabapentin in the treatment of drug-resistant epileptic patients. In: Manelis J, Bental E, Loeber JN, Dreifuss FE, eds. Proceedings of The XVIIth Epilepsy International Symposium. New York, Raven Press, 1989:219-21 (Advances in epileptology, vol. 17).
44. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
45. Asconapé J, Collins T. Weight gain associated with the use of gabapentin. Epilepsia 1995;36(suppl 4):S72.
46. King JA, Bayles RL. Weight gain during add-on therapy using gabapentin (GBP). Epilepsia 1995;36(suppl 4):S72
47. Cugley AL, Swartz BE. Gabapentin-associated mood changes? Epilepsia 1995;36(suppl 4):S72.
48. Schantz D, Towbin JA, Spitz MD. Changes in mood and affect in patients on gabapentin, Epilepsia 1995;36(suppl 4):S73.
49. Zupane ML, Schroeder VM. Behavioral changes in children on Gabapentin. Epilepsia 1995;36(suppl 4):S73.
50. Reeves AL, So EL, Sharbrough FW, Krahn LE. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-90.
51. Graves NM, Leppik IE, Wagner ML, Spencer MM, Erdmann GR. Effect of gabapentin on carbamazepine levels. Epilepsia 1990;31:644-5.
52. Graves NM, Holmes GB, Leppik IE, Rask C, Slavin M, Anhut H. Pharmacokinetics of gabapentin in patients treated with phenytoin. Pharmacotherapy 1989;9:196.
53. Uthman BM, Hammond EJ, Wilder BJ. Absence of gabapentin and valproate interaction: an evoked potential and pharmacokinetic study. Epilepsia 1990;31:645.
54. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-7.
55. Anhut H, Ashman P, Feurstein TJ, et al, and the International Gabapentin Study Group. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebocontrolled study, Epilepsia 1994;35:795-801.
56. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36(suppl 6):S10-13.
57. Gustavson LE, Cato A, Guenther HJ, et al. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin or valproate. Epilepsia 1995;36(suppl 3):S159-60.
58. Richens A, Gustavson LE, McKelvy JF, Mangel H, Deaton R, Pierce MW. Pharmacokinetics and safety of single-dose tiagabine HCl in epileptic patients chronically treated with four other antiepileptic drug regimens. Epilepsia 1991;32(suppl 3):S12.
59. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995;22:221-6.
60. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995;36(suppl 6):S7-9.
61. Schapei G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996;5:153-6.
62. Leppik IE. Felbamate. Epilepsia 1995;36(suppl 2):S66-72.
63. Felbamate. Physicians' Desk Reference. Montvale, NJ; Medical Economics, 1996:2266-70.
64. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:386-92.
65. Wagner ML, Remmel RP, Graves NM, Leppik IE, Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993:536-43.
66. Graves NM, Holmes GB, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989;30:225-9.
67. Wagner ML, Graves NM, Leppik IE, Remmel RD, Ward DL, Shumaker RC. The effect of felbamate on valproate disposition. Epilepsia 1991;32:15.
68. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for partial seizures. Neurology 1995;45:456-60.
69. Anonymous. Acute liver failure linked to felbamate use. Am J Hosp Pharm 1994;51:2282, 2287.
70. Ney GC, Schaul N, Loughlin J, Rai K, Chandra V. Thrombocytopenia in association with adjunctive felbamate use. Neurology 1994;44:980-1.
71. Reife RA. Topiramate. In: Shorvon S, Dreifuss F, Fish D, Thomas D, eds. The treatment of epilepsy. Oxford: Blackwell Science, 1996:471-81.
72. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S18-22.
73. Reife RA, Lim P, Pledger G. Topiramate: side effect profile in double-blind studies. Epilepsia 1995;36(suppl 4):S34.
74. Wasserstein A, Reife R, Rak I. Topiramate and nephrolithiasis. Epilepsia 1995;36(suppl 3):S153.
75. Wasserstein A, Reife R, Rak I. Mechanistic basis for topiramateassociated nephrolithiasis. Epilepsia 1995;36(suppl 3):S153.
76. Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S14-7.
77. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nyak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8): S54.
78. Gisclon LG, Curtin CR, Kramer LD. The steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):S4.
79. Liao S, Rosenfeld WE, Palmer M, et al. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):S117.